Skip to search formSkip to main contentSkip to account menu

J591 monoclonal antibody

Known as: J591 MAb, Monoclonal Antibody J591, J591 
Monoclonal recombinant antibody J591 (mAb HuJ591) recognizes the extracellular domain of prostate specific membrane antigen (PSMA), a cell surface… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.
272 Background: PSMA targeted therapy has recently emerged as a promising approach for patients with advanced prostate cancer… 
2013
2013
Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer
Radioimmunotherapy (RIT) has demonstrated efficacy with acceptable toxicity leading to approval in non-Hodgkin’s lymphoma, but… 
2013
2013
Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).
31 Background: Presently, there are no means of accurately and reproducibly imaging bone metastases for patients with mCRPC. We… 
2012
2012
Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
This study investigated the feasibility of targeting the free, unbound forms of prostate-specific antigen (fPSA) for in vivo… 
2010
2010
Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant…
4667 Background: A phase II trial of single-dose 177Lu-J591 radioimmunotherapy (RIT) in pts with metCRPC demonstrated efficacy… 
2008
2008
Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer…
5140 Background: A phase 1 trial of 177Lu-J591 in pts with metCRPC demonstrated acceptable toxicity, excellent targeting of met… 
2007
2007
Phase II trial of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 plus low-dose interleukin-2 (IL-2) in patients (pts) with recurrent prostate cancer (PC)
15558 Background: The de-immunized mAb J591 recognizes the extracellular domain of PSMA and was engineered to induce antibody… 
Review
2006
Review
2006
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
Prostate cancer represents an ideal target for radioimmunotherapy based on the pattern of spread, including bone marrow and lymph… 
Highly Cited
2004
Highly Cited
2004
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice
Prostate specific membrane antigen (PSMA), expressed by virtually all prostate cancers is an ideal target for targeted therapy of… 
2004
2004
Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?
Determination of the immunoreactive fraction (IF) of radiolabeled monoclonal antibodies (MAb) is essential to the understanding… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)